Tags

Type your tag names separated by a space and hit enter

One year update on the COVID-19 pandemic: Where are we now?
Acta Trop. 2021 Feb; 214:105778.AT

Abstract

We are living through an unprecedented crisis with the rapid spread of the new coronavirus disease (COVID-19) worldwide within a short time. The timely availability of thousands of SARS-CoV-2 genomes has enabled the scientific community to study the origin, structures, and pathogenesis of the virus. The pandemic has spurred research publication and resulted in an unprecedented number of therapeutic proposals. Because the development of new drugs is time consuming, several strategies, including drug repurposing and repositioning, are being tested to treat patients with COVID-19. Researchers have developed several potential vaccine candidates that have shown promise in phase II and III trials. As of 12 November 2020, 164 candidate vaccines are in preclinical evaluation, and 48 vaccines are in clinical evaluation, of which four have cleared phase III trials (Pfizer/BioNTech's BNT162b2, Moderna's mRNA-1273, University of Oxford & AstraZeneca's AZD1222, and Gamaleya's Sputnik V vaccine). Despite the acquisition of a vast body of scientific information, treatment depends only on the clinical management of the disease through supportive care. At the pandemic's 1-year mark, we summarize current information on SARS-CoV-2 origin and biology, and advances in the development of therapeutics. The updated information presented here provides a comprehensive report on the scientific progress made in the past year in understanding of SARS-CoV-2 biology and therapeutics.

Links

PMC Free PDF

Authors+Show Affiliations

Mishra SK
Department of Botany, Ewing Christian College, Prayagraj- 211003, Uttar Pradesh, India.
Tripathi T
Molecular and Structural Biophysics Laboratory, Department of Biochemistry, North-Eastern Hill University, Shillong 793022, Meghalaya, India. Electronic address: timir.tripathi@gmail.com.

MeSH

Adenosine MonophosphateAlanineAmidesAnimalsAntiviral AgentsCOVID-19COVID-19 VaccinesChloroquineClinical Trials as TopicCoronavirusCoronavirus InfectionsDrug CombinationsDrug RepositioningGlucocorticoidsHumansHydroxychloroquineIndolesIvermectinLopinavirMutationPandemicsPhytotherapyPlant ExtractsPyrazinesRitonavirSARS-CoV-2Spike Glycoprotein, CoronavirusTinosporaViral Zoonoses

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33253656

Citation

Mishra, Sanjay Kumar, and Timir Tripathi. "One Year Update On the COVID-19 Pandemic: Where Are We Now?" Acta Tropica, vol. 214, 2021, p. 105778.
Mishra SK, Tripathi T. One year update on the COVID-19 pandemic: Where are we now? Acta Trop. 2021;214:105778.
Mishra, S. K., & Tripathi, T. (2021). One year update on the COVID-19 pandemic: Where are we now? Acta Tropica, 214, 105778. https://doi.org/10.1016/j.actatropica.2020.105778
Mishra SK, Tripathi T. One Year Update On the COVID-19 Pandemic: Where Are We Now. Acta Trop. 2021;214:105778. PubMed PMID: 33253656.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - One year update on the COVID-19 pandemic: Where are we now? AU - Mishra,Sanjay Kumar, AU - Tripathi,Timir, Y1 - 2020/11/28/ PY - 2020/09/05/received PY - 2020/11/23/revised PY - 2020/11/24/accepted PY - 2020/12/1/pubmed PY - 2021/2/17/medline PY - 2020/11/30/entrez KW - COVID-19 KW - Coronavirus KW - Drug repurposing KW - Outbreak KW - Pandemic KW - Pathogenesis KW - SARS-CoV-2 KW - Therapeutics KW - Vaccines SP - 105778 EP - 105778 JF - Acta tropica JO - Acta Trop VL - 214 N2 - We are living through an unprecedented crisis with the rapid spread of the new coronavirus disease (COVID-19) worldwide within a short time. The timely availability of thousands of SARS-CoV-2 genomes has enabled the scientific community to study the origin, structures, and pathogenesis of the virus. The pandemic has spurred research publication and resulted in an unprecedented number of therapeutic proposals. Because the development of new drugs is time consuming, several strategies, including drug repurposing and repositioning, are being tested to treat patients with COVID-19. Researchers have developed several potential vaccine candidates that have shown promise in phase II and III trials. As of 12 November 2020, 164 candidate vaccines are in preclinical evaluation, and 48 vaccines are in clinical evaluation, of which four have cleared phase III trials (Pfizer/BioNTech's BNT162b2, Moderna's mRNA-1273, University of Oxford & AstraZeneca's AZD1222, and Gamaleya's Sputnik V vaccine). Despite the acquisition of a vast body of scientific information, treatment depends only on the clinical management of the disease through supportive care. At the pandemic's 1-year mark, we summarize current information on SARS-CoV-2 origin and biology, and advances in the development of therapeutics. The updated information presented here provides a comprehensive report on the scientific progress made in the past year in understanding of SARS-CoV-2 biology and therapeutics. SN - 1873-6254 UR - https://www.unboundmedicine.com/medline/citation/33253656/One_year_update_on_the_COVID_19_pandemic:_Where_are_we_now DB - PRIME DP - Unbound Medicine ER -